Neurontin Class Action To Include Generics Buyers

Law360, New York (March 24, 2008, 12:00 AM EDT) -- A Philadelphia judge has ruled that Pfizer Inc. can be held liable for off-label marketing of generic versions of its blockbuster epilepsy drug Neurontin, allowing a class action including people who bought both brand-name and generic Neurontin to go forward.

On March 14, Judge Mark Bernstein of the Philadelphia County Court of Common Pleas denied a motion by Pfizer for partial summary judgment that a class action against it could not include patients who were prescribed gabapentin, the generic version of Neurontin. Judge Bernstein cited several...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.